Global Anticoagulant Reversal Drugs Databank Market Report

Global Anticoagulant Reversal Drugs Databank Market Report

The Anticoagulant Reversal Drugs market was valued at $751.6 Million in 2022, and is projected to reach $2,176.4 Million by 2031 growing at a CAGR of 12.61% from 2023 to 2031. Idarucizumab segment is expected to be the highest contributor to this market, with $288.6 Million in 2022, and is anticipated to reach $799.0 Million by 2031, registering a CAGR of 12.05%. Phytonadione segment is anticipated to reach $189.8 Million by 2031 with the highest CAGR of 15.75%. Idarucizumab and Andexanet Alfa segments collectively expected to account for about 64.9% share of the Anticoagulant Reversal Drugs market in 2022, with the former constituting around 38.4% share. Phytonadione and Protamine segments are expected to witness significant growth rates at a CAGR of 15.75% and 15.51% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 9.5% in the overall Anticoagulant Reversal Drugs market in 2022, and is anticipated to reach 12.2% by 2031.